Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment-Reference-Cited by-同舟云学术

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Published:2017-04-10 Issue:2 Volume:66 Page:389-397
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Poordad Fred¹,Felizarta Franco²,Asatryan Armen³,Sulkowski Mark S.⁴,Reindollar Robert W.⁵,Landis Charles S.⁶,Gordon Stuart C.⁷,Flamm Steven L.⁸,Fried Michael W.⁹,Bernstein David E.¹⁰,Lin Chih‐Wei³,Liu Ran³,Lovell Sandra S.³,Ng Teresa I.³,Kort Jens³,Mensa Federico J.³

Affiliation:

1. Texas Liver InstituteUniversity of Texas Health Science CenterSan Antonio TX

2. Private PracticeBakersfield CA

3. AbbVie IncNorth Chicago IL

4. Johns Hopkins University School of MedicineBaltimore MD

5. Piedmont Healthcare/Carolinas Center for Liver DiseaseStatesville NC

6. Division of GastroenterologyUniversity of WashingtonSeattle WA

7. Henry Ford Health SystemDetroit MI

8. Northwestern Feinberg School of MedicineChicago IL

9. University of North CarolinaChapel Hill NC

10. North Shore University HospitalManhasset NY

Funder